Attovia Therapeutics, Inc. ATTO
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -30.64%
- 1 year
- -30.64%
- Open
- 15.30
- Prev close
- 15.27
- Mkt cap
- 693.44M
- Vol
- 146.67K
- Avg vol
- 437.49K
- EPS
- -2.74
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.77
- High
- 15.99
- Forward P/E
- -9.30
- Beta
- 0.00
- Short ratio
- 0.54
- Inst. own
- 40.86%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 21.62
- 200-d avg
- 21.62
- 1y target
- 42.20
2Y chart
Events in this range
- Aug 31, 2026Rating: Morgan Stanley · — → Overweight
- Aug 31, 2026Rating: RBC Capital · — → Outperform
- Aug 31, 2026Rating: Leerink Partners · — → Outperform
- Aug 31, 2026Rating: LifeSci Capital · — → Outperform
- Aug 31, 2026Rating: Citigroup · — → Buy
- Sep 2, 2026Earnings: -4.88; estimate -0.6459; surprise -655.53%
Signals (3)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 26, 2026 | 5 days ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 12, 2026 | 2 weeks ago |
Key statistics
- Market cap
- 1.01B
- Enterprise value
- 1.19B
- Trailing P/E
- 0.00
- Forward P/E
- -9.30
- PEG ratio
- 0.00
- Price / sales
- 561.51
- Price / book
- 0.00
- EPS (TTM)
- -1.64
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.80M
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 115.13M
- Total debt
- 4.33M
- Return on equity
- 0.00%
- Shares outstanding
- 45.65M
- Short % of float
- 0.00%
- 50-day average
- 21.62
- 200-day average
- 21.62
Analyst view
Consensus: strong buy
- Target (low)
- 30.00
- Target (mean)
- 42.20
- Target (high)
- 52.00
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.50.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Sep 2, 2026 | Jun 30, 2026 | -0.6459 | -4.88 | -4.23 | -655.53% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 31, 2026 | Citigroup | init | — | Buy |
| Aug 31, 2026 | LifeSci Capital | init | — | Outperform |
| Aug 31, 2026 | Leerink Partners | init | — | Outperform |
| Aug 31, 2026 | RBC Capital | init | — | Outperform |
| Aug 31, 2026 | Morgan Stanley | init | — | Overweight |
About Attovia Therapeutics, Inc.
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- attovia.com
News
- Attovia Therapeutics to Participate in Upcoming Investor Conferences
- Attovia Therapeutics To Present New Clinical, Translational, And Preclinical Data Across Its Pipeline At EADV Congress And FCD 2026
- Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026
- Attovia Therapeutics, Inc. (ATTO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- Quanex Building Products, Concrete Pumping, SanDisk And Other Big Stocks Moving Higher On Friday
- Attovia Therapeutics to Participate in Upcoming Investor Conferences
- Attovia Therapeutics Q2 EPS $(4.88) Misses $(4.62) Estimate, Sales $450.000K
- Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
- Citigroup Initiates Coverage On Attovia Therapeutics with Buy Rating, Announces Price Target of $30
- LifeSci Capital Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $45
Your note
Sign in to keep a note on ATTO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DEEP TRACK BIOTECHNOLOGY MASTER FUND LTD | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Aug 5, 2026 | 0 |
| FRAZIER LIFE SCIENCES X, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 5, 2026 | 0 |
| FRAZIER LIFE SCIENCES XI , L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 5, 2026 | 0 |
| GOLDMAN SACHS GROUP INC. | Unknown | Purchase | Aug 5, 2026 | 0 |
| GOLDMAN SACHS GROUP, INC. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 5, 2026 | 0 |
| REDMILE GROUP, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 5, 2026 | 0 |